Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 1112 results for criteria

  1. Cochlear implants for children and adults with severe to profound deafness (TA566)

    Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.

  2. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  3. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

  4. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

    Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.

  5. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges (NG11)

    This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.

  6. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

  7. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (HST32)

    Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.

  8. Buy books, journals and databases

    Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.

  9. Platelet-rich plasma injections for knee osteoarthritis (IPG637)

    Evidence-based recommendations on platelet-rich plasma injections for knee osteoarthritis in adults. This involves taking plasma from a small amount of the person’s own blood and injecting it into the knee.

  10. Social work with adults experiencing complex needs (NG216)

    This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.

  11. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

  12. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  13. High-intensity focused ultrasound for symptomatic benign thyroid nodules (IPG643)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic benign thyroid nodules in adults. This involves using heat made by high-frequency sound waves to destroy the nodule.

  14. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)

    Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.

  15. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making